Gender disparities and associated factors to intention to getting a second dose of COVID-19 AstraZeneca vaccine among adult populations in selected facilities of Lusaka, Zambia.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
01
2022
accepted:
16
06
2022
entrez:
24
3
2023
pubmed:
25
3
2023
medline:
25
3
2023
Statut:
epublish
Résumé
As COVID-19 vaccines are becoming more available, there is also a growing need to understand the population receiving the doses, existing inequalities and the intention to getting the second vaccine dose among the populations that receive the vaccines. We evaluated gender inequalities and intention to uptake of the second dose of COVID-19 AstraZeneca vaccine among adult populations in selected urban facilities of Lusaka, Zambia. A cross-sectional study design was conducted between May and June 2021 among adults who received AstraZeneca vaccine from three selected urban facilities of Lusaka, Zambia. Phone-based interviews were conducted 6 weeks after the first dose of the vaccine. Descriptive analysis and mixed-effect logistic regression were done using STATA version 16.2. Of the 1321 adults who had received AstraZeneca vaccine, 868 respondents completed the questionnaire. About, 47% (408/868) were females and 53% (460/868) were males. Median age in the study was 40 years. Majority of males were educated (54%) and employed (57%). Furthermore, majority of females that got the first dose of AstraZeneca reported experiencing side effects (76.98%) compared to males (64.24%). Among study participants, 93.7% intended to receive the AstraZeneca vaccine, of whom 46.7% (380/814) were females and 52.9% (434/814) were males. Majority of participants that did not intend to get a second dose were not married (55.56%). Only age (AOR, 1.05; 95% CI, 1.02-1.08) predicted intention to getting a second dose of AstraZeneca vaccine. We found important gender-dependent differences in the side effects reported by females that received the first dose of Astra Zeneca. Finding that intention to get the second dose of the vaccine increased with age suggests a need for enhancing COVID-19 vaccination programmes targeting young people and a need for further research to identify specific adverse effects of COVID-19 Astra Zeneca vaccines.
Identifiants
pubmed: 36962377
doi: 10.1371/journal.pgph.0000265
pii: PGPH-D-22-00093
pmc: PMC10021410
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0000265Informations de copyright
Copyright: © 2022 Jacobs et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
Hum Vaccin Immunother. 2022 Dec 31;18(1):1-6
pubmed: 34227914
Health Care Women Int. 2020 Nov-Dec;41(11-12):1370-1383
pubmed: 33030978
Vaccines (Basel). 2021 Feb 16;9(2):
pubmed: 33669441
Med Princ Pract. 2021;30(3):262-271
pubmed: 33486492
Nat Rev Immunol. 2020 Oct;20(10):583-584
pubmed: 32908300
Infect Dis Rep. 2021 Oct 11;13(4):888-901
pubmed: 34698203
Nat Rev Microbiol. 2020 Mar;18(3):123
pubmed: 31988490
BMC Public Health. 2018 Dec 11;18(1):1364
pubmed: 30537969
Brain Behav Immun. 2021 May;94:41-50
pubmed: 33713824
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Vaccine. 2021 Jul 13;39(31):4343-4350
pubmed: 34154863
Nat Med. 2021 Aug;27(8):1385-1394
pubmed: 34272499
JAMA. 2020 Jun 23;323(24):2458-2459
pubmed: 32421155
Pers Individ Dif. 2021 Apr;172:110590
pubmed: 33518869
Ann Glob Health. 2021 Jul 23;87(1):72
pubmed: 34327119
Soc Sci Med. 2005 Sep;61(5):989-1000
pubmed: 15955401
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Paediatr Respir Rev. 2020 Sep;35:43-49
pubmed: 32653463
MMWR Morb Mortal Wkly Rep. 2021 Feb 05;70(5):174-177
pubmed: 33539333
Lancet. 2021 Jan 9;397(10269):72-74
pubmed: 33306990
J Clin Med. 2021 Apr 01;10(7):
pubmed: 33916020
Biomed Pharmacother. 2020 Nov;131:110748
pubmed: 33152916
Hum Vaccin Immunother. 2021 Oct 3;17(10):3421-3432
pubmed: 34292140